What is ACE-031 (Ramatercept)?

Soluble ActRIIB-Fc fusion decoy receptor. DMD Phase 2 halted in 2013 due to epistaxis and telangiectasia from vascular off-target effects. ACE-031 is a soluble ActRIIB receptor fused to an Fc domain that sequesters myostatin, activin, and GDF-11. Program was halted for vascular off-targets.

What is ACE-031 (Ramatercept) used for?

Reported uses include raises lean mass in preclinical and phase 1 studies. Evidence strength is rated Clinical — see the evidence section for detail.

How is ACE-031 (Ramatercept) dosed?

Commonly referenced dosing is Historical trial doses, typically trial-dependent, administered SubQ. This is educational reference only; consult a licensed clinician before use.

What are the side effects of ACE-031 (Ramatercept)?

Commonly reported side effects include epistaxis, telangiectasia, and vascular off-targets. This list is not exhaustive.

ACE-031 (Ramatercept) | Peptide Guide

§ 01 Overview

Overview

Soluble ActRIIB-Fc fusion decoy receptor. DMD Phase 2 halted in 2013 due to epistaxis and telangiectasia from vascular off-target effects.

DMD Phase 2 halted 2013 for safety.

§ 02 Mechanism

Mechanism of action

ACE-031 is a soluble ActRIIB receptor fused to an Fc domain that sequesters myostatin, activin, and GDF-11. Program was halted for vascular off-targets.

01Raises lean mass in preclinical and Phase 1 studies

§ 03 Dosing

Dosing protocol

Standard Protocol

Dose Range: Historical trial doses
Route: SubQ
Frequency: Trial-dependent

§ 04 Evidence

Evidence & research

Clinical

DMD Phase 2 halted 2013 for safety.

FDA Status

Not FDA-approved. Program discontinued.

§ 07 Sourcing

Sourcing & supply

Regulatory status

Investigational, no compounding path

Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09 Safety

Safety & side effects

Side effects

01Epistaxis
02Telangiectasia
03Vascular off-targets

Contraindications

None specified.

§ 10 Questions

ACE-031 (Ramatercept) FAQ

What is ACE-031 (Ramatercept)?: Soluble ActRIIB-Fc fusion decoy receptor. DMD Phase 2 halted in 2013 due to epistaxis and telangiectasia from vascular off-target effects. ACE-031 is a soluble ActRIIB receptor fused to an Fc domain that sequesters myostatin, activin, and GDF-11. Program was halted for vascular off-targets.
What is ACE-031 (Ramatercept) used for?: Reported uses include raises lean mass in preclinical and phase 1 studies. Evidence strength is rated Clinical — see the evidence section for detail.
How is ACE-031 (Ramatercept) dosed?: Commonly referenced dosing is Historical trial doses, typically trial-dependent, administered SubQ. This is educational reference only; consult a licensed clinician before use.
What are the side effects of ACE-031 (Ramatercept)?: Commonly reported side effects include epistaxis, telangiectasia, and vascular off-targets. This list is not exhaustive.
Is ACE-031 (Ramatercept) legal?: Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Not FDA-approved. Program discontinued..

§ 11 References

Selected references

01
Attie Muscle Nerve 2013
PMID: 23625875
02
DMD Phase 2 (discontinued)
NCT01099761
03
Campbell 2017 review
PMID: 27462804